Antisense Pharma Receives FDA Orphan Drug Designation for Trabedersen to Treat Malignant Melanoma
The biopharmaceutical company Antisense Pharma GmbH announces that the US Food and Drug Administration (FDA) has granted…
The biopharmaceutical company Antisense Pharma GmbH announces that the US Food and Drug Administration (FDA) has granted…
The biopharmaceutical company Antisense Pharma announces the appointment of Dr. Philippe Calais as CEO. The native-born…
The biopharmaceutical company Antisense Pharma announced today that MIG Funds 2, 3 and 9 as well as GAF have increased t…
At the international cancer congress ASCO 2011 in Chicago, USA, the biopharmaceutical company Antisense Pharma presented…
Antisense Pharma GmbH, a biopharmaceutical company headquartered in Germany, has announced the granting of patents for a…
The German company Antisense Pharma is dedicated to the development of antisense-technology based anticancer drugs. Rece…
The biopharmaceutical company Antisense Pharma today announced that the South Korean health agency KFDA as well as the T…
The biopharmaceutical company Antisense Pharma announced today that their international, randomized and active-controlle…
During this year's BIOTECHNICA exhibition, the international biotech news magazine "GEN - Genetic Engineering & Biotechn…
The biopharmaceutical company Antisense Pharma announced today that the US-American Food and Drug Administration (FDA) h…